Full formMedical & Health
HGGstands forHigh Grade Glioma
Full Form of HGG
What is HGG?
High Grade Glioma (HGG) is an aggressive type of brain tumour that originates from glial cells and is classified as Grade III or IV under the World Health Organization (WHO) grading system. In India, HGG accounts for a significant proportion of primary brain malignancies, often presenting with symptoms such as persistent headaches, seizures, and neurological deficits. Diagnosis relies on advanced imaging like MRI and histopathological confirmation after biopsy. Treatment typically involves maximal safe surgical resection followed by radiotherapy and chemotherapy with temozolomide. In India, specialized neuro-oncology centres in metropolitan cities like Mumbai, Delhi, and Bengaluru manage HGG cases, though access to timely care remains a challenge in rural areas. The acronym HGG is frequently encountered in medical literature, neurosurgery discussions, and oncology board exams. For medical students preparing for NEET PG and other postgraduate entrance tests, understanding HGG’s molecular markers, such as IDH mutation and MGMT promoter methylation, is crucial for prognosis and management. Despite advances, HGG carries a poor prognosis, highlighting the need for early detection and multidisciplinary care.
HGG का फुल फॉर्म
उच्च श्रेणी का ग्लियोमा
Example
The patient was diagnosed with HGG after MRI revealed an enhancing mass in the frontal lobe, and she was immediately scheduled for debulking surgery.
HGG — frequently asked questions
What is the full form of HGG?
The full form of HGG is High Grade Glioma, which refers to an aggressive type of brain tumour originating from glial cells.
What are the common symptoms of HGG in Indian patients?
Common symptoms include persistent headaches, seizures, nausea, vomiting, and progressive neurological deficits such as weakness or speech difficulties.
How is HGG treated in India?
Treatment typically involves surgical resection, followed by radiotherapy and chemotherapy with temozolomide. Some centres offer targeted therapies based on molecular profiling.